These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 29867531)
21. Altered gut microbiota and intestinal permeability in Parkinson's disease: Pathological highlight to management. Sharma S; Awasthi A; Singh S Neurosci Lett; 2019 Nov; 712():134516. PubMed ID: 31560998 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665 [TBL] [Abstract][Full Text] [Related]
23. Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for PD prevention. Lee Y; Lee S; Chang SC; Lee J Arch Pharm Res; 2019 May; 42(5):416-425. PubMed ID: 30830660 [TBL] [Abstract][Full Text] [Related]
29. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. Hattori N Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506 [TBL] [Abstract][Full Text] [Related]
30. Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson's Disease. Videira PAQ; Castro-Caldas M Front Neurosci; 2018; 12():381. PubMed ID: 29930494 [TBL] [Abstract][Full Text] [Related]
31. Differential role of Dok1 and Dok2 in TLR2-induced inflammatory signaling in glia. Downer EJ; Johnston DG; Lynch MA Mol Cell Neurosci; 2013 Sep; 56():148-58. PubMed ID: 23659921 [TBL] [Abstract][Full Text] [Related]
34. Mitochondrial dysfunction in Parkinson's disease. Hu Q; Wang G Transl Neurodegener; 2016; 5():14. PubMed ID: 27453777 [TBL] [Abstract][Full Text] [Related]
35. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Collins LM; Toulouse A; Connor TJ; Nolan YM Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232 [TBL] [Abstract][Full Text] [Related]
36. Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease. Chiang HL; Lin CH J Mov Disord; 2019 May; 12(2):67-83. PubMed ID: 31158941 [TBL] [Abstract][Full Text] [Related]
37. Lack of PINK1 alters glia innate immune responses and enhances inflammation-induced, nitric oxide-mediated neuron death. Sun L; Shen R; Agnihotri SK; Chen Y; Huang Z; Büeler H Sci Rep; 2018 Jan; 8(1):383. PubMed ID: 29321620 [TBL] [Abstract][Full Text] [Related]
38. The Gut and Nonmotor Symptoms in Parkinson's Disease. Klingelhoefer L; Reichmann H Int Rev Neurobiol; 2017; 134():787-809. PubMed ID: 28805583 [TBL] [Abstract][Full Text] [Related]
39. The Enemy within: Innate Surveillance-Mediated Cell Death, the Common Mechanism of Neurodegenerative Disease. Richards RI; Robertson SA; O'Keefe LV; Fornarino D; Scott A; Lardelli M; Baune BT Front Neurosci; 2016; 10():193. PubMed ID: 27242399 [TBL] [Abstract][Full Text] [Related]
40. Mitochondria: A Therapeutic Target for Parkinson's Disease? Luo Y; Hoffer A; Hoffer B; Qi X Int J Mol Sci; 2015 Sep; 16(9):20704-30. PubMed ID: 26340618 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]